Comparative Pharmacology
Head-to-head clinical analysis: HYGROTON versus METAHYDRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYGROTON versus METAHYDRIN.
HYGROTON vs METAHYDRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter (NCC), leading to increased excretion of sodium, chloride, and water.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
25-50 mg orally once daily; may increase to 100 mg once daily for resistant hypertension or edema. Maximum dose 100 mg/day.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 40-50 hours, extending up to 70 hours in patients with renal impairment, allowing for once-daily dosing.
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
Renal (approximately 50-60% as unchanged drug and metabolites); biliary/fecal elimination accounts for a minor fraction, less than 10%.
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic